[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-352293-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-352293-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-role-of-androgen-receptor-and-antiandrogen-therapy-in-breast-cancer-a-scoping-review","The Role of Androgen Receptor and Antiandrogen Therapy in Breast Cancer: A Scoping Review","","Breast cancer is a complex, heterogeneous disease, and management increasingly follows precision medicine principles. This scoping review analyzes the role of the androgen receptor (AR) as a therapeutic target, especially in triple-negative breast cancer (TNBC) subgroups that express AR. It details AR biology, contrasting functions across ER-positive and TNBC contexts, and examines key antiandrogen clinical trials, including enzalutamide and other agents. It also addresses limitations such as resistance, biomarker needs, AR expression heterogeneity, and future directions including combinations and improved predictive testing.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-role-of-androgen-receptor-and-antiandrogen-therapy-in-breast-cancer-a-scoping-review/352293/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-role-of-androgen-receptor-and-antiandrogen-therapy-in-breast-cancer-a-scoping-review/352293.png","ImageObject",300,407,{"name":42,"@type":43},"Olivia Brown","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is androgen receptor (AR) considered a therapeutic target in breast cancer?","Question",{"text":63,"@type":64},"AR is a nuclear hormone receptor found in many breast cancers, including subsets of triple-negative breast cancer, and may influence tumor development and growth in a context-dependent manner.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does AR function differently across breast cancer subtypes?",{"text":68,"@type":64},"AR activity may vary depending on molecular context, with differential function described between ER-positive tumors and TNBC subtypes, including the luminal androgen receptor (LAR) subgroup.",{"name":70,"@type":61,"acceptedAnswer":71},"What are the main challenges for using antiandrogen therapy in clinical practice?",{"text":72,"@type":64},"The review highlights modest overall benefits, concentration of responses in carefully selected patients, and issues such as primary/acquired resistance and the need for robust predictive biomarkers.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},352293,1790196396,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Review  \nThe Role of Androgen Receptor and Antiandrogen Therapy in Breast Cancer: A Scoping Review  \nAntonio Ghidini 1, Roberta Bukovec 1, Luisa Roncari 1, Isabella Garassino 1, Fulvia Milena Cribiù 2 and Fausto Petrelli 3, *  \nReceived: 2 December 2025  \nRevised: 26 December 2025  \nAccepted: 5 January 2026  \nPublished: 12 January 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Oncology Unit, Casa di Cura Igea, 20129 Milano, MI, Italy; [a.ghidini@casadicuraigea.it](a.ghidini@casadicuraigea.it) (A.G.); [r.bukovec@casadicuraigea.it](r.bukovec@casadicuraigea.it) (R.B.); [luisa.roncari@alice.it](luisa.roncari@alice.it) (L.R.); [isabella.garassino@virgilio.it](isabella.garassino@virgilio.it) (I.G.)  \n2 Patology Unit, ASST Bergamo Ovest, 24047 Treviglio, BG, Italy; fulvia_[cribiu@asst-bgovest.it](cribiu@asst-bgovest.it)  \n3 Oncology Unit, ASST Bergamo Ovest, 24047 Treviglio, BG, Italy  \n* Correspondence: [fausto_petrelli@asst-bgovest.it](fausto_petrelli@asst-bgovest.it)  \nSimple Summary  \nBreast cancer is not one disease but many different types that behave differently and need different treatments. Most therapies target the female hormones, estrogen and progesterone, but another hormone receptor, called the androgen receptor, is also found in many breast cancers, including some aggressive tumors that lack the usual treatment targets. This review summarizes what is currently known about how the androgen receptor affects breast cancer development and how medicines that block it may help certain patients. We describe how the androgen receptor works inside cells, why it may slow tumor growth in some breast cancers but support growth in others, and what clinical studies have reported so far for antiandrogen drugs. Overall, benefits have generally been modest, and responses appear concentrated in carefully selected patients, meaning these treatments are not yet routine care. We also explain why resistance can occur and why better laboratory tests are needed to identify who is most likely to benefit. Finally, we outline future directions, including combining androgen receptor-blocking drugs with other treatments and using modern blood-and tissue-based testing to personalize therapy over time. This work is valuable because it may guide the development of new options for patients with limited choices while helping avoid ineffective treatment.  \nAbstract  \nBreast cancer is a complex and highly heterogeneous disease, and its management is increasingly moving towards the principles of precision medicine. In this context, the androgen receptor (AR) has emerged as a promising therapeutic target, particularly within the challenging subgroup of triple-negative breast cancers (TNBCs) that express it. This scoping review provides a comprehensive and detailed analysis of the multifaceted role of AR in breast cancer. We delve into its intricate molecular structure, its differential function in ER-positive vs. TNBC subtypes, and the detailed molecular mechanisms that govern its activity. We provide a thorough examination of the landmark clinical trials with antiandrogen agents, including not only enzalutamide but also other first-and secondgeneration compounds, and discuss the emerging data on their efficacy. Furthermore, we will explore the critical challenges that hinder their widespread clinical adoption, such as primary and acquired resistance mechanisms, the need for robust predictive biomarkers, and the heterogeneity of AR expression. Finally, we outline future research directions, focusing on novel combination therapies and the development of next-generation agents and predictive tools to optimize patient selection and improve clinical outcomes.  \nKeywords: androgen receptor; triple-negative breast cancer; luminal androgen receptor; antiandrogen therapy; enzalutamide; bicalutamide;","cbCaiqMCRBfIfT26","https://ap.wps.com/l/cbCaiqMCRBfIfT26","pdf",954946,13,"English","# Introduction\n## Molecular classification and subtypes of breast cancer\n## Triple-negative breast cancer (TNBC) heterogeneity and prognosis\n## Androgen receptor (AR) as a therapeutic target","[{\"question\":\"Why is androgen receptor (AR) considered a therapeutic target in breast cancer?\",\"answer\":\"AR is a nuclear hormone receptor found in many breast cancers, including subsets of triple-negative breast cancer, and may influence tumor development and growth in a context-dependent manner.\"},{\"question\":\"How does AR function differently across breast cancer subtypes?\",\"answer\":\"AR activity may vary depending on molecular context, with differential function described between ER-positive tumors and TNBC subtypes, including the luminal androgen receptor (LAR) subgroup.\"},{\"question\":\"What are the main challenges for using antiandrogen therapy in clinical practice?\",\"answer\":\"The review highlights modest overall benefits, concentration of responses in carefully selected patients, and issues such as primary/acquired resistance and the need for robust predictive biomarkers.\"}]","The Role of Androgen Receptor and Antiandrogen Therapy in Breast Cancer: A Scoping Review | PDF",1790098787,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fbf41519259e51ba8509c327a588b6b9.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bebca9aa4a100d96fb80ffe6489d3299.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/338392e787f10865cd3942118c829633.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fac446d551e045e0b6d9b86c23f501e4.webp",980,1385]